You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5391 Results
Guidelines and Advice
Status: Current
ID: GL 5-3ORG
Version: 2
Apr 2019
Guidelines and Advice
Status: Current
ID: GL END 5-13
Version: N/A
Jun 2023
Guidelines and Advice
Status: Current
ID: 5-2
Version: 2
Oct 2023
Guidelines and Advice
Status: Current
ID: 5-9
Version: 2
Jan 2020
Guidelines and Advice
Status: Current
ID: GL END 5-7
Version: 3
Nov 2021
Guidelines and Advice
Status: Current
ID: 5-11
Version: 2
Jan 2022
Drug
Other Name(s): Alecensaro®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
vinCRIStine,
procarbazine,
cytarabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
alectinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Document
New
Dec 2025
Document
New
Dec 2025
Document
New
Dec 2025

Pages